Prescient Metabiomics has received FDA breakthrough status for its non-invasive colorectal cancer test. The test, called LifeKit Prevent, identifies microbial DNA and RNA biomarkers associated with the new, abnormal growth of tissue in the gastrointestinal tract. By detecting these changes in the microbiome, Prescient says it can identify patients with precancerous polyps and early stage carcinomas, resulting in more people getting treated before the disease progresses.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
bacteria
binx health
Biosimilar
Blood Filter
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
colorectal cancer
Diagnostics
Digital Health
Drug Discovery
ExThera Medical
FDA
FDA approval
funding
fundraising
glycosylation
Halodoc
HIV
Innovation
Licensing
M&A
medical device
medtech
microbial
microbial DNA
microbial RNA
microbiome
Neuro
Novartis
pharma
Pharming
Prescient Metabiomics
robots
software
Therapeutics
Therapy
USA
VIrology
women health